780 Targeting myeloid cells with BO-112 engages T cell immunity in combination with radiotherapy and checkpoint blockade in preclinical models and a phase 1 neoadjuvant clinical trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Regular and Young Investigator Award Abstracts

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Myeloid

Show all topics

DOI

10.1136/jitc-2024-sitc2024.0780

License

CC-BY-NC

Other Formats

PDF